Obesity in pregnancy: obstetric complications and outcomes

Dr Kelly-Ann Eastwood
Academic Clinical Lecturer in Obstetrics and Gynaecology
ASO Northern Ireland regional group meeting
24th January 2018
The scale of the problem

- Global issue
- Major implications for individual and public health

Classification of obesity

Class I
(30.0 - 34.99 kg/m$^2$)

Class II
(35.0 - 39.99 kg/m$^2$)

Class III
(≥40.0 kg/m$^2$)

(World Health Organization, 2015)
Obesity in pregnancy

• 58% women in England are overweight / obese

• Almost 50% of pregnant women are classified as overweight or obese (Scott-Pillai et al., 2013)

• 5%–6% of women are in obese classes II or III

  Translates to **38,478** births annually

• 0.19% of all women giving birth in the UK are super morbidly obese (BMI ≥ 50 kg/m²) (CMACE, 2010)
Physiological changes

Stirrat and Reynolds, 2014
Reilly and Rader, 2003
Challenges facing the obstetric team

1. Antenatal
2. Intrapartum
3. Postpartum
Antenatal challenges

Maternal complications

• Hypertensive disorders of pregnancy (16%)
  ✓ Pre-eclampsia
  ✓ Pregnancy induced hypertension

• Gestational diabetes (8%)
• Venous thromboembolism

Fetal complications

• Miscarriage
• Stillbirth (8.6 v 3.9 per 1,000 LB)
• Preterm delivery (7%)
• Congenital anomaly
• Macrosomia (23%)
• Growth restriction (4%)

Scott-Pillai et al., 2013
O’Brien, Ray and Chan, 2003
CEMACE, 2010
Bhattacharya et al., 2007
Modified antenatal care

**Essential care**

- Appropriate BP monitoring
- Aspirin (75mg, BMI>35)
- VTE risk assessment (?LMWH)
- Vitamin D (10mcg)
- High dose folic acid (5mg)
- Glucose tolerance test (BMI>30)
- Anaesthetic r/v (BMI>40)

**Desirable care**

- Preconception counselling
- Specialist antenatal clinic

---

CMACE/RCOG Joint Guideline

Management of Women with Obesity in Pregnancy
Fetal surveillance

• Growth monitoring
  ✓ Attendance for regular growth scans in third trimester (BMI >35 kg/m²)

• Detection of fetal anomaly
  ✓ 1-3 fold increase in risk of neural tube defects
  ✓ Increased risk of congenital heart disease (OR 1.44 for class III)

Rasmussen et al., 2008
Persson et al., 2017
• Retrospective cohort study
• Analysis of 500 anomaly scans
• 19+0 – 21+6 weeks gestation
• Women were categorised according to the WHO BMI classification
• Fetal anomaly imaging scoring system developed from the NHS Fetal Anomaly Screening Programme standard to evaluate scans

• 52% of scans incomplete in obese class III v 12% in normal weight class
• 33% of four chamber cardiac views and 38% of outflow tract views were not obtained in obese class III

Conclusion: Maternal obesity has a significant impact on completion of foetal anomaly screening.
Technicalities

- Increased depth of insonation
- Previous c/s
- Equipment
- Occupational injury
- Increased scanning time

Pai-Jong et al., 2015
Paladini, 2009
Hunsley and Farrell, 2014
Intrapartum considerations

- Fetal monitoring

- Anaesthetic complications
  - Regional anaesthesia
  - Risk of failed intubation (1:3)
  - Increased risk of aspiration

- Increased likelihood of induction of labour (OR 1.4)
- Increased risk of emergency caesarean section (OR 1.8)
- Postpartum haemorrhage (OR 2.4)

Gupta and Faber, 2011
Scott Pillai et al., 2010
CEMACE/RCOG, 2010
Postpartum complications

Maternal:
- Venous thromboembolism
- Wound infection / breakdown (OR 3.5)
- Increased length of hospital stay
- Independently associated with risk of dying

Neonatal:
- Complications of prematurity
- ICU admission
- Increased length of hospital stay
- Cerebral palsy
- Death

Scott-Pillai et al., 2013
MBRRACE-UK, 2014
Paladini, 2009
The future

Improved maternal and neonatal outcomes
• Pyramid model of prenatal care (Ministry of Health, 1930)
• Challenging existing pathways of care (Nicolaides, 2011)
• Combined screening tools increase predictive value of screening models (Poon et al. 2010, Audibert et al. 2010)
The PREDICT study

• Clinical utility of 3D Doppler ultrasound and maternal biomarkers in the prediction of pre-eclampsia in high-risk women
• Prospective longitudinal observational study
• 4 groups of high-risk women

1. Diabetes (treatment for >1 year)
2. Obesity (BMI >35 kg/m²)
3. Hypertension
   (IUGR, PE, chronic hypertension, renal disease)
4. Thrombophilia / autoimmune disease

• n=232 (including 30 low risk controls)
Methodology

1. Uterine artery Doppler

2. 3D Power Doppler placental imaging

3. Maternal serum biomarkers
   - Imbalance between circulating angiogenic & anti-angiogenic factors
   - Angiogenic and anti-angiogenic markers: [PlGF, sFlt-1, sEng]
   - HbA1c, PAPP-A, FABP4
3D power Doppler

• Non-invasive means of assessing placental vascularisation and flow indices
• Whole placental volume (VOCAL- Virtual Organ Computer-aided AnaLysis) technique
• Virtually reconstructed vascular tree within a volume of interest
• Based on measurement of ‘voxels’
  [represents a value on a regular grid in 3-dimensional space]
What are we measuring?

1. **Vascularisation index (%) (VI)**
   ✓ Ratio of colour voxels to all voxels with the volume of interest (%) [number of vessels]

2. **Flow index (FI)**
   ✓ Mean power Doppler signal intensity from all colour voxels (unit-less) [intensity of flow]

3. **Vascularisation flow index (VFI)**
   ✓ $\text{VI} \times \text{FI} / 100$ (unit-less) [ratio of blood flow and vascularisation]
1. Identify the placental mass using 2D greyscale imaging

Locate and position the placental mass within the image acquisition box

2. Acquire placental volume image using 3D power Doppler

Proceed to volume analysis

3. Manual tracing method of the placental border via $30^0$ rotations (6 rotations)

Generate a volume histogram to obtain placental vasularisation indices (VI (%), FI, VFI)

(Alcázar, 2008)
Maternal obesity and 1st trimester PVIs

- n=116 (11+0-13+6 weeks)
- Complete imaging in 109 women (94%)
- Adiposity documented as a restricting factor in 97%
- BMI had a significant negative impact on image quality and degree of difficulty (P<0.001)
- BMI had a significant impact on FI (P<0.001) and VFI (P<0.05)
- Stepwise reductions across increasing BMI categories
Take home messages

• Public health issue

• Impact on maternal and neonatal outcomes

• Service provision

• Service improvement

• Future screening models in obese women:
  ✓ Suitable cut points for PVIs
  ✓ Threshold ranges for biomarkers
Acknowledgements

• **Funders:** R&D office, The Puffin Trust

• **Supervisors:**
  - Prof Ian Young
  - Dr Valerie Holmes
  - Prof David Mc Cance
  - Dr Alyson Hunter

• Dr Jennifer Badham
• Dr Faleeha Khanum